Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 20, 2026, 8:08 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–37 of 13 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Healthy Volunteer
Interventions
Alectinib, Esomeprazole, High Fat and Calorie Meal, Standard Meal
Drug · Other
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 55 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Austin, Texas
Conditions
ALK+ Advanced NSCLC
Interventions
Brigatinib, Alectinib
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
248 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
4
States / cities
Whittier, California • Athens, Georgia • Albany, New York + 1 more
Conditions
Non-small Cell Lung Cancer
Interventions
Alectinib, Entrectinib, Vemurafenib, Cobimetinib, Pralsetinib, Atezolizumab, SBRT, Resection, Chemotherapy, Divarasib
Drug · Procedure
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
38
States / cities
Duarte, California • Irvine, California • Los Angeles, California + 28 more
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Alectnib, Cisplatin, Vinorelbine, Gemcitabine, Pemetrexed, Carboplatin
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
257 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2031
U.S. locations
3
States / cities
Chicago, Illinois • Boston, Massachusetts • Pittsburgh, Pennsylvania
Conditions
Locally Advanced Solid Tumor, Metastatic Solid Tumor
Interventions
Neladalkib (NVL-655), Midazolam, Repaglinide, Itraconazole
Drug
Lead sponsor
Nuvalent Inc.
Industry
Eligibility
12 Years and older
Enrollment
840 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
21
States / cities
Orange, California • Sacramento, California • Stanford, California + 16 more
Conditions
Brain Metastasis, Stereotactic Radiosurgery, Resection, Systemic Therapy
Interventions
Systemic therapy
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Houston, Texas
Conditions
Anaplastic Lymphoma Kinase, Anaplastic Large Cell Lymphoma
Interventions
Alectinib, Duvelisib
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Conditions
Non-Small Cell Lung Cancer (NSCLC)
Interventions
Alectinib, Bevacizumab
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Healthy Volunteer
Interventions
Alectinib, Posaconazole
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 55 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Austin, Texas
Conditions
Cancer
Interventions
Atezolizumab, Bevacizumab, Alectinib, Cobimetinib, Vemurafenib, FAP IL2V, Venetoclax, Enzalutamide, Pembrolizumab, Sunitinib, Niraparib, Cabozantinib, Pemetrexed, Paclitaxel, Emactuzumab, Rucaparib
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
7
States / cities
Aurora, Colorado • Trumbull, Connecticut • Boston, Massachusetts + 3 more
Conditions
ALK Fusion-positive Solid or CNS Tumors
Interventions
Alectinib
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
Up to 17 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2032
U.S. locations
7
States / cities
Palo Alto, California • St. Petersburg, Florida • Ann Arbor, Michigan + 4 more
Conditions
Non-Small-Cell Lung Carcinoma
Interventions
Erlotinib, Alectinib
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
17
States / cities
Birmingham, Alabama • Fullerton, California • Orange, California + 14 more
Conditions
Lung Non-Squamous Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions
Alectinib, Brigatinib, Carboplatin, Ceritinib, Cisplatin, Crizotinib, Ensartinib, Lorlatinib, Pemetrexed
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
491
States / cities
Goodyear, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 341 more